Peter Joseph Leary MD PhD
Pulmonary Vascular Medicine
Professor of Medicine and Epidemiology (Adjunct) at the University of Washington
Join to View Full Profile
1959 Ne Pacific StSeattle, WA 98195
Phone+1 206-598-4615
Fax+1 206-598-3036
Dr. Leary is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Peter Leary is the Director of the Pulmonary Vascular Disease Program at the University of Washington, a board-certified pulmonologist, and a Professor of Medicine and Epidemiology. His grant funded research program is focused on identifying and targeting mechanisms that contribute to pulmonary hypertension and heart failure.
Education & Training
University of Washington School of Public HealthPhD, Epidemiology, 2013 - 2018- University of Washington School of Public HealthMS, Epidemiology , 2010 - 2013
University of WashingtonFellowship, Pulmonary Disease and Critical Care Medicine, 2009 - 2012
Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2009- Johns Hopkins University School of MedicineClass of 2005
Certifications & Licensure
WA State Medical License 2009 - 2026
American Board of Internal Medicine Pulmonary Disease
National Board of Physicians and Surgeons Critical Care Medicine- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Pulmonary Disease
Clinical Trials
- Beraprost-314d Added-on to Tyvaso® (BEAT) Start of enrollment: 2013 May 31
- OPsumit USers Registry Start of enrollment: 2014 Apr 30
- U.S. CTEPH Registry Start of enrollment: 2015 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Reply to Tung and Chang and to SuntharalingamSamuel G Rayner, Rachel J Le, Peter J Leary, John Hartney, Nathan Hatton
American Journal of Respiratory and Critical Care Medicine. 2025-07-01 - Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.Peter J Leary, Samuel G Rayner, Kelley R H Branch, Laurie Hogl, Nancy M Liston
Chest. 2025-07-01 - The landscape of referrals for lung transplantation in pulmonary arterial hypertension: A report from the Pulmonary Hypertension Association Registry.Nicholas A Kolaitis, Jonathan P Singer, Sonja Bartolome, Murali M Chakinala, Daniel Grinnan
The Journal of Heart and Lung Transplantation. 2025-06-27
Press Mentions
COVID Vaccine for Patient with Rare Disease? Best Guess Is YesJanuary 21st, 2021
Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular CarcinomaNovember 3rd, 2020
I'm Aware That I'm Rare: Peter Leary, MD (PE Part 2 of 2)September 25th, 2017- Join now to see all
Grant Support
- REVAMP-PH: REpurposing Valsartan May Protect against Pulmonary HypertensionUNIVERSITY OF WASHINGTON2024–2028
- REVAMP-PH: REpurposing Valsartan May Protect against Pulmonary HypertensionUNIVERSITY OF WASHINGTON2024–2028
- The Pulmonary Hypertension- Multi-Dimensional Omics to Characterize Right Heart Adaptation (PH-MOCHA) studyUNIVERSITY OF WASHINGTON2020–2025
Professional Memberships
- Member
- Member
- Pulmonary Hypertension Association - PHAMember
- Pulmonary Vascular Research Institute - PVRIMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
